Statins revisited: therapeutic applications beyond lipid lowering?

[1]  A. Diegeler,et al.  Statin loading before coronary artery bypass grafting: a randomized trial. , 2023, European heart journal.

[2]  I. V. Van Gelder,et al.  2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. , 2021, European heart journal.

[3]  F. Carreras,et al.  Intravenous Statin Administration During Myocardial Infarction Compared With Oral Post-Infarct Administration. , 2020, Journal of the American College of Cardiology.

[4]  G. Vilahur,et al.  Molecular pathways involved in the cardioprotective effects of intravenous statin administration during ischemia , 2019, Basic Research in Cardiology.

[5]  M. Sabatine,et al.  2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. , 2019, European heart journal.

[6]  M. Banach,et al.  Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease , 2019, Expert opinion on pharmacotherapy.

[7]  G. Vilahur,et al.  Intravenous Statin Administration During Ischemia Exerts Cardioprotective Effects. , 2019, Journal of the American College of Cardiology.

[8]  Luciano de Moura Santos,et al.  Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial , 2018, JAMA.

[9]  U. Laufs,et al.  Pleiotropic Effects of Statins on the Cardiovascular System , 2017, Circulation research.

[10]  R. Collins,et al.  Perioperative Rosuvastatin in Cardiac Surgery. , 2016, The New England journal of medicine.

[11]  Cesare R Sirtori,et al.  The pharmacology of statins. , 2014, Pharmacological research.

[12]  V. Pasceri,et al.  Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. , 2009, Journal of the American College of Cardiology.

[13]  Michael Schachter,et al.  Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update , 2005, Fundamental & clinical pharmacology.

[14]  S. Wolfe.  Dangers of rosuvastatin identified before and after FDA approval , 2004, The Lancet.